Psychiatric Genomics Consortium
The Psychiatric Genomics Consortium (PGC) is an international
psychiatric disorders. It is the largest psychiatric consortium ever created,[1] including over 800 researchers from 38 countries as of 2019.[2] Its goal is to generate information about the genetics of psychiatric conditions that will be "actionable", that is, "genetic findings whose biological implications can be used to improve diagnosis, develop rational therapeutics, and craft mechanistic approaches to primary prevention".[1] The consortium makes the main findings from its research freely available for use by other researchers.[3]
History
The PGC was founded in early 2007, originally as the Psychiatric Genome Wide Association Consortium.public-private partnership aimed at researching the genetics of human disorders in general.[6]
For its first four years of existence, the PGC focused on
single nucleotide polymorphisms that were associated with psychiatric disorders. Since then, it has expanded its scope to include other disorders, as well as less common forms of genetic variation such as copy number variation.[2]
Findings
Research from the PGC has shed light on the
genetic loci that are consistently associated with schizophrenia.[6] In addition, its findings have pointed to significant pleiotropy across psychiatric disorders, with many common alleles influencing the risk of multiple such disorders.[4]
References
- ^ PMID 28969442.
- ^ a b c "What is the PGC?". Psychiatric Genomics Consortium. Retrieved 2019-06-05.
- PMID 26994396.
- ^ PMID 26407777.
- ^ "New Genetic Risk Factors Discovered for Alzheimer's Disease". UNC Health Care (Press release). 2019-01-07. Retrieved 2019-06-05.
- ^ PMID 25904361.